Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant Recipients

Pharmaceutics

Kwaku Marfo¹  Jerry Altshuler² 

[1] Montefiore-Einstein Transplant Center,111 East 210th Street, Bronx, NY 10467, USA;School of Pharmacy, State University at Buffalo, 110 Cooke Hall, Buffalo, NY 14215, USA

关键词: tacrolimus;    FK-506;    pharmacokinetics;    pharmacogenomics;    pediatric transplant;   

DOI  :  10.3390/pharmaceutics2030291

来源: mdpi

【 摘 要 】

Tacrolimus is a calcineurin inhibitor immunosuppressant that has seen considerable use in both adult and pediatric solid organ transplant recipients. Though there is much pharmacokinetic data available for tacrolimus in the adult population, the literature available for children is limited. Furthermore, very little is known about the pharmacogenomic differences in the two patient groups. Based on what information is currently available, clinically significant differences may exist between the two populations in terms of absorption, distribution, metabolism and elimination. In addition, inherent physiological differences exist in the young child including: less effective plasma binding proteins, altered expression of intestinal P-glycoprotein, and increased expression of phase 1 metabolizing enzymes, therefore one would expect to see clinically significant differences when administering tacrolimus to a child. This paper examines available literature in an attempt to summarize the potential pharmacokinetic and pharmacogenomic variability that exists between the two populations.

【 授权许可】

CC BY   
© 2010 by the authors; licensee MDPI, Basel, Switzerland.